Smart Money Still Has Faith in Zimmer Biomet Holdings, Inc. (NYSE:ZBH)

Paterniano Del Favero
Luglio 17, 2017

Over the past twelve months, Zimmer Biomet Holdings, Inc. OLD Mutual Customised Solutions Proprietary Ltd.'s holdings in Zimmer Biomet Holdings were worth $380,000 as of its most recent SEC filing.

Want to see what other hedge funds are holding ZBH? Nordea Investment Management AB now owns 4,931,281 shares of the medical equipment provider's stock worth $602,159,000 after buying an additional 987,398 shares during the last quarter. Finally, First Manhattan Co. raised its position in Zimmer Biomet Holdings by 13.5% in the first quarter.

Stratos Wealth Partners LTD. boosted its position in shares of Zimmer Biomet Holdings, Inc. The medical equipment provider reported $2.13 EPS for the quarter, beating the Thomson Reuters' consensus estimate of $2.11 by $0.02. The value of the company's investment in Zimmer Biomet Holdings, Inc. went from $16,215,000 to $16,972,000 a change of 4.7% since the last quarter. Levin Capital Strategies L.P. now owns 556,036 shares of the medical equipment provider's stock worth $57,383,000 after buying an additional 164,132 shares in the last quarter. Nordea Investment Management AB raised its position in Zimmer Biomet Holdings by 25.0% in the first quarter. Institutional investors and hedge funds own 84.17% of the company's stock. Zimmer Biomet Holdings, Inc. has a 52-week low of $95.63 and a 52-week high of $133.21. (NYSE:ZBH) traded at an unexpectedly high level on 07/14/2017 when the stock experienced a 2.72% gain to a closing price of $132.49. Analysts expect that Zimmer Biomet Holdings will post $8.52 EPS for the current year. After $2.16 actual earnings per share reported by Travelers Companies Inc for the previous quarter, Wall Street now forecasts -3.70% negative EPS growth. The firm has a 50 day moving average of $123.43 and a 200-day moving average of $117.75.

Zimmer Biomet Holdings (NYSE:ZBH) last issued its quarterly earnings data on Thursday, April 27th. The dividend will be $0.240 per share for the quarter which is $0.96 annualized. The business had revenue of $1.98 billion for the quarter, compared to analysts' expectations of $1.96 billion. Zimmer Biomet Holdings had a net margin of 6.36% and a return on equity of 16.80%. Breaking that down further, it has performed 4.23% for the week, 5.49% for the month, 10.84% over the last quarter, 15.78% for the past half-year and 4.91% for this a year ago. During the same quarter a year ago, the business posted $2.00 EPS. In the latest earnings report the EPS was $2.44 and is expected to be $8.52 for the current year with 201,644,000 shares now outstanding.

The company also recently announced a quarterly dividend, which will be paid on Friday, July 28th. Stockholders of record on Friday, June 23rd will be issued a dividend of $0.24 per share. The ex-dividend date has been established as Wednesday the 21st of June 2017. Zimmer Biomet Holdings's dividend payout ratio is presently 39.67%.

TRADEMARK VIOLATION NOTICE: This story was first posted by Sports Perspectives and is the property of of Sports Perspectives. If you are accessing this report on another domain, it was illegally stolen and republished in violation of worldwide copyright legislation. The legal version of this story can be accessed at https://sportsperspectives.com/2017/07/16/oppenheimerfunds-inc-lowers-position-in-zimmer-biomet-holdings-inc-zbh-updated-updated.html. Piper Jaffray Companies reaffirmed a "buy" rating and issued a $141.00 target price on shares of Zimmer Biomet Holdings in a research report on Friday.

In a report issued on June 29, Jefferies also reiterated a Buy rating on the stock with a $148 price target. On August 23 Barclays maintained a company rating of "Overweight" and moved up the price target from $140.00 to $145.00. Stifel Nicolaus reaffirmed a "hold" rating and issued a $125.00 target price on shares of Zimmer Biomet Holdings in a research report on Friday. UBS downgraded the shares of ZBH in report on Thursday, December 15 to "Sell" rating. The company now has an average rating of "Buy" and a consensus price target of $137.19. The shares were sold at an average price of $124.56, for a total transaction of $2,208,573.36. In the last ninety days, insiders have sold 111,262 shares of company stock worth $13,103,927. The transaction was disclosed in a filing with the SEC, which is available at this link.

In related news, insider David C. Dvorak sold 87,331 shares of the stock in a transaction on Thursday, April 27th. The shares were sold at an average price of $116.76, for a total value of $723,912.00.

Altre relazioni OverNewsmagazine

Discuti questo articolo

SEGUI I NOSTRI GIORNALE